Log In
BCIQ
Print this Print this
 

Cypher Select

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionSirolimus-eluting stent
Molecular Target FK506 binding protein 1A 12kDa (FKBP1A) (FKBP12)
Mechanism of ActionMammalian target of rapamycin (mTOR) kinase inhibitor
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentMarketed
Standard IndicationIschemia / reperfusion injury
Indication DetailsTreat severe claudication and critical limb ischemia (CLI) of infrapopliteal lesions
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today